Cerevel Therapeutics Holdings Inc

CERE

NASDAQ. Currency in USD

28.37 -0.59 ( -2.04% )

Real time prices: December 01

Market Cap.
4.43B
Beta (5Y monthly)
1.64
Price/Earnings
-
EPS (TTM)
-2.13
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
402,564
1y Target Est.
40.40
Day's Range
27.52
-
28.97
52 Week's Range
19.86
-
41.46

Historical Summary

Performance
EPS growth
Share Buybacks

About Cerevel Therapeutics Holdings Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.cerevel.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
147.24M
Employees
285
Address
222 Jacobs Street, Cambridge, MA, United States, 02141
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Latest news

Cerevel Therapeutics to Present at Upcoming Investor Conferences
Cerevel Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated...
By GlobeNewswire Inc. - 2 weeks ago

What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg
What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg

Over the past 3 months, 8 analysts have published their opinion on Cerevel Therapeutics Hldg...
By Benzinga - 3 weeks ago

Tyson Foods To $61? Plus Needham Slashes PT On This Stock By 33%
Tyson Foods To $61? Plus Needham Slashes PT On This Stock By 33%

B of A Securities cut the price target on Tyson Foods, Inc. (NYSE: TSN) from...
By Benzinga - 3 weeks ago

Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates
Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

Completed $599 million dual convertible debt and equity financing to advance a robust neuroscience therapeutics...
By GlobeNewswire Inc. - 3 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Upgrades For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio...
By Benzinga - 4 weeks ago

What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg
What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg

Cerevel Therapeutics Hldg (NASDAQ:CERE) has observed the following analyst ratings within the last quarter: Bullish...
By Benzinga - 6 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022

Upgrades According to Credit Suisse, the prior rating for Hudson Pacific Properties Inc (NYSE:HPP) was...
By Benzinga - 6 weeks ago

Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022
Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022

CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated...
By GlobeNewswire Inc. - 6 weeks ago